NCT00725751View on ClinicalTrials.gov

Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

CompletedOBSERVATIONAL
Enrollment

353

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

Pegylated interferon alfa-2b (PegIFN-2b)

PegIFN-2b administered according to European labeling.

DRUG

Ribavirin

Ribavirin administered according to European labeling.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00725751 - Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) | Biotech Hunter | Biotech Hunter